Search





Search





News

All

Editors' Picks

Stocks

Indices

Market Movers

Commodities

Cryptocurrencies

Forex

Earnings

Transcripts

Technical Analysis

Economic Indicator

Other

Allogene Therapeutics (ALLO) Q2 2026 Earnings Call: ALPHA3 Site Expansion and Pipeline Updates

Allogene Therapeutics’ Q2 2026 earnings call covers ALPHA3’s 100-site target, FDA designations, ALLO-316 results and ALLO-329’s Q4 update.

Allogene Therapeutics Inc

TradingKey

4 hours ago

Applied Materials (AMAT) Fiscal Q3 2026 Earnings Call: Revenue Hits $9.1 Billion

Applied Materials fiscal Q3 2026 revenue rose 25% to $9.1 billion. AMAT guided Q4 revenue to $10.25 billion as AI, DRAM and packaging demand strengthened.

Applied Materials Inc

TradingKey

4 hours ago

Altimmune (ALT) Q2 2026 Earnings Call: PERFORMA Starts, Cash Reaches $519M

Altimmune Q2 2026 earnings call: PERFORMA Phase III enrollment begins, RECLAIM AUD data support pivotal planning, and cash reaches $519 million.

TradingKey

4 hours ago

AIRO Q2 2026 Earnings Call: Revenue Jumps 76%, Drone Backlog Reaches $163M

AIRO Q2 2026 earnings call: revenue rose 76% to $43.2 million, gross margin reached 64%, drone backlog hit $163 million, and guidance was reiterated.

AIRO Group Holdings Inc

TradingKey

4 hours ago

AIxCrypto Holdings (AIXC) Q2 2026 Earnings Call: RoboShare Push Amid Tight Liquidity

AIxCrypto Holdings (AIXC) Q2 2026 earnings call: net loss narrowed sequentially to $4.19 million as RoboShare became the priority amid tight liquidity.

AIxCrypto Holdings Ord Shs

TradingKey

4 hours ago

AFCG Q2 2026 Earnings Call: NAV Rises, Pipeline Reaches $1.3 Billion

AFCG’s Q2 2026 earnings call covered $3.5 million in net investment income, $8.25 NAV per share, a 13.2% portfolio yield and a $1.3 billion pipeline.

Advanced Flower Capital Inc

TradingKey

4 hours ago

Applied Industrial Technologies (AIT) Fiscal Q4 2026 Earnings Call: Organic Sales Rise 9.7%

Applied Industrial Technologies’ fiscal Q4 2026 sales rose 10.4% as margins expanded. Review AIT’s segment results and fiscal 2027 guidance.

Applied Industrial Technologies Inc

TradingKey

4 hours ago

AudioEye (AEYE) Q2 2026 Earnings Call: EBITDA Guidance Raised

AudioEye Q2 2026 revenue rose 9% to $10.7 million, ARR reached $42.3 million, and management raised full-year adjusted EBITDA guidance.

TradingKey

4 hours ago

Aebi Schmidt (AEBI) Q2 2026 Earnings Call: EBITDA Up 22%, Backlog Near $1.3B

Aebi Schmidt Q2 2026 earnings call: sales rose 9.4% to $496 million, adjusted EBITDA gained 22%, backlog reached $1.3 billion, and guidance was confirmed.

Aebi Schmidt Holding AG

TradingKey

4 hours ago

ADC Therapeutics (ADCT) Q2 2026 Earnings Call: LOTIS-5 FDA Concerns, $219.1M Cash

ADC Therapeutics Q2 2026 earnings call: ZYNLONTA revenue reached $18.6 million, while FDA concerns clouded the LOTIS-5 regulatory path.

ADC Therapeutics SA

TradingKey

4 hours ago

Aethlon Medical (AEMD) Fiscal Q1 2027 Earnings Call: Oncology Trial Enters Final Cohort

Aethlon Medical’s fiscal Q1 2027 call covered $1.6M in operating expenses, $4.9M in cash and progress in the final oncology trial cohort.

Aethlon Medical Inc

TradingKey

4 hours ago

Alpha Cognition (ACOG) Q2 2026 Earnings Call: ZUNVEYL Sales Rise 71%

Alpha Cognition’s Q2 2026 earnings call covered $6.0M in ZUNVEYL sales, 71% sequential growth, stronger adoption and lower expense guidance.

Alpha Cognition Inc

TradingKey

4 hours ago

Abeona Therapeutics (ABEO) Q2 2026 Earnings Call: ZEVASKYN Revenue Rises 31%

Abeona Therapeutics (ABEO) Q2 2026 earnings call: ZEVASKYN revenue rose 31% QoQ to $11.4M, seven QTCs were active, and cash totaled $146.8M.

Abeona Therapeutics Inc

TradingKey

4 hours ago

AADX Q2 2026 Earnings Call: Revenue Rises 47.4%, Backlog Tops $1.1 Billion

Applied Aerospace & Defense's Q2 2026 earnings call covered 47.4% revenue growth, backlog above $1.1 billion and maintained full-year guidance.

Applied Aerospace and Defense Ord Shs

TradingKey

4 hours ago

Acumen Pharmaceuticals (ABOS) Q2 2026 Earnings Call: ALTITUDE-AD Readout Due Late 2026

Acumen Pharmaceuticals’ Q2 2026 earnings call covered $110.2 million in cash, the late-2026 ALTITUDE-AD readout and its mid-2027 EBD IND target.

Acumen Pharmaceuticals Inc

TradingKey

4 hours ago

1...7 8 9 10 11

11/11

Featured Tools

marketing_marketsTitle

calendar_economicCalendar

Economic Calendar

search.intelligent.strategy

article_asider_weekly_report

Popular Instruments

link

Name

Price

Chg%

link

【US Pre-Market】PPI in Focus After CPI Cools; Cisco Drops Over 6%, Applied Materials Earnings in Spotlight

Google Launches Gemini 3.7 Flash: Major Leap in Coding and Agent Capabilities, Three-Week Iteration Sets New Speed Record for Low-Cost Models

Micron Stock Forecast: Can AI Memory Demand Push MU Above $1,000?

Oracle Stock Forecast: ORCL Faces Layoffs, $70B Capex and Rising Debt

US Stocks Close: S&P 500 Hits Record High, Nasdaq Gains for Second Day; Memory Stocks Lead as SanDisk Surges Over 13%

link

BNB (BNBUSD) Is down 1.05% on Aug 14: Why It Happened

41 minutes ago

Solana (SOLUSD) Is down 1.08% on Aug 14: Why It Happened

56 minutes ago

NZD/USD (NZDUSD) Is up 0.52% on Aug 14: What Signals Does the Macro Data Send?

3 hours ago

WTI Futures (USOIL-F) Surges on Aug 14: Key Factors to Watch

5 hours ago

WTI (USOIL) Is up 2.30% on Aug 14: Is the Market Repricing It?

5 hours ago